{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:36:51Z","timestamp":1792795011323,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diversity of study populations in clinical trials is essential to addressing health outcome disparities in cancer care. The objective of this study was to examine the inclusion of minority race\/ethnicity groups in breast cancer clinical trials published in the United States of America (USA) 2012\u20132022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Breast cancer clinical trials published as a full manuscript in the USA 2012\u20132022 were identified. Trial characteristics and race\/ethnicity of subjects were collected to assess the degree of reporting and inclusion of minority populations. Participation to Prevalence Ratios (PPRs) were utilized as a measure of inclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 1068 trials (\n                      <jats:italic>n<\/jats:italic>\n                      = 871,683 subjects), race\/ethnicity was reported in 785 (73.5%), increasing from 2012 to 2016 (68.8%) to 2017 to 2022 (79.3%,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Higher rates of race\/ethnicity reporting were independently associated with later publication year, randomized or phase II trials, and those reporting social determinants of health. Of the 732,969 subjects for whom race\/ethnicity was reported, 16,551 (2.3%) were Asian American\/Pacific Islander (Asian), 43,288 (5.9%) were Black\/African American, 22,464 (3.1%) were Hispanic\/Latinx, and 570,897 (77.9%) were Non-Hispanic White. A PPR above 0.8 was achieved in 27.3% of trials that reported race for Asian subjects, 44.7% for Black\/African American subjects, 27.4% for Hispanic\/Latinx subjects, and in 5.7% for all three minority groups. All four primary race groups in the USA were represented in 24.7% of trials, and race\/ethnicity was included as a factor in outcome analysis in 8.7%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although race\/ethnicity reporting has improved, minority populations remain gravely underrepresented in breast cancer clinical trials, limiting the generalizability of trial results in these populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19214-y","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T14:20:45Z","timestamp":1771856445000},"page":"5541-5549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Examining the Representation of Minority Race and Ethnicity Groups in Breast Cancer Clinical Trials in the USA Published 2012\u20132022"],"prefix":"10.1245","volume":"33","author":[{"given":"Katrina","family":"Dimaano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Otilio","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Moazzez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Ozao-Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1766-6680","authenticated-orcid":false,"given":"Christine","family":"Dauphine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"19214_CR1","unstructured":"National Institutes of Health: Grant\u2019s and Funding. https:\/\/grants.nih.gov\/policy\/clinical-trials\/definition.htm (2023). Accessed 29 Dec 2023."},{"key":"19214_CR2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(23)00182-1","volume":"24","author":"SA McIntosh","year":"2023","unstructured":"McIntosh SA, Alam F, Adams L, et al. Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments. Lancet Oncol. 2023;24:636\u201345.","journal-title":"Lancet Oncol"},{"key":"19214_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074684","volume":"381","author":"C Taylor","year":"2023","unstructured":"Taylor C, McGale P, Probert J, et al. Breast cancer mortality in 500,000 women with early invasive breast cancer diagnosed in England, 1993\u20132015: population based observational cohort study. BMJ. 2023;381:e074684.","journal-title":"BMJ."},{"key":"19214_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-030-20301-6_3","volume":"1152","author":"CG Yedjou","year":"2019","unstructured":"Yedjou CG, Sims JN, Miele L, et al. Health and racial disparity in breast cancer. Adv Exp Med Biol. 2019;1152:31\u201349.","journal-title":"Adv Exp Med Biol."},{"key":"19214_CR5","unstructured":"U.S. Department of Health and Human Services Policy Statement on Inclusion of Race and Ethnicity in DHHS Data Collection Activities. https:\/\/aspe.hhs.gov\/collaborations-committees-advisory-groups\/hhs-data\/hhs-data-council-introduction\/dc-archive\/policy-statement-inclusion-race-ethnicity-dhhs-data-collection-activities (2023). Accessed 27 Dec 2023"},{"key":"19214_CR6","unstructured":"Institute of Medicine (US) Committee on Ethical and Legal Issues Relating to the Inclusion of Women in Clinical Studies. In: Mastroianni AC, Faden R, Federman D, editors. Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies. Volume I. Washington (DC): National Academies Press (US); 1994. B, NIH Revitalization Act of 1993 Public Law 103-43. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK236531\/."},{"issue":"7","key":"19214_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jama.2021.13304","volume":"326","author":"A Flanagin","year":"2021","unstructured":"Flanagin A, Frey T, Christiansen SL. Updated guidance on the reporting of race and ethnicity in medical and science journals. JAMA. 2021;326(7):621\u20137.","journal-title":"JAMA."},{"key":"19214_CR8","unstructured":"National Library of Medicine PubMed: www.pubmed.ncbi.nlm.nih.gov (2022). Accessed Dec 2022."},{"issue":"3","key":"19214_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1001\/jamaoncol.2021.6968","volume":"8","author":"S Chen","year":"2022","unstructured":"Chen S, Li J, Shu M. Use of participation to prevalence ratio for evaluating the representation status of women in oncology clinical trials. JAMA Oncol. 2022;8(3):479\u201380.","journal-title":"JAMA Oncol."},{"key":"19214_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.15585\/mmwr.mm7102a2","volume":"71","author":"TD Ellington","year":"2022","unstructured":"Ellington TD, Miller JW, Henley JH, Wilson RJ, Wu M, Richardson LC. Trends in breast cancer incidence, by race, ethnicity, and age among women aged \u226520 years \u2013 united states, 1999\u20132018. MMWR Morb Mortal Wkly Rep. 2022;71:43\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"19214_CR11","unstructured":"U.S. Department of Health and Human Services: Office for Human Research Protections, The Belmont Report. https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/belmont-report\/index.html (2024). Accessed 9 Jan 2024."},{"key":"19214_CR12","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2105\/AJPH.2011.300279","volume":"101","author":"JA Fisher","year":"2011","unstructured":"Fisher JA, Kalbaugh CA. Challenging assumptions about minority participation in US research. Am J Public Health. 2011;101:2217\u201322.","journal-title":"Am J Public Health."},{"issue":"10","key":"19214_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870","volume":"5","author":"JM Loree","year":"2019","unstructured":"Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1870.","journal-title":"JAMA Oncol."},{"issue":"4","key":"19214_CR14","doi-asserted-by":"publisher","first-page":"pkaa034","DOI":"10.1093\/jncics\/pkaa034","volume":"4","author":"JM Unger","year":"2020","unstructured":"Unger JM, Hershman DL, Osarogiagbon RU, et al. Representativeness of Black patients in cancer clinical trials sponsored by the National Cancer Institute compared with pharmaceutical companies. JNCI Cancer Spectr. 2020;4(4):pkaa034.","journal-title":"JNCI Cancer Spectr."},{"key":"19214_CR15","unstructured":"American Cancer Society: Breast cancer facts and figures 2022-2024. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/breast-cancer-facts-figures.html (2024). Accessed 9 Jan 2024."},{"issue":"12","key":"19214_CR16","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1245\/s10434-023-14201-z","volume":"30","author":"G Keegan","year":"2023","unstructured":"Keegan G, Crown A, DiMaggio C, Joseph K. Insufficient reporting of race and ethnicity in breast cancer clinical trials. Ann Surg Oncol. 2023;30(12):7008\u201314.","journal-title":"Ann Surg Oncol."},{"key":"19214_CR17","unstructured":"United States Census Bureau: Examining the racial and ethnic diversity of adults and children. https:\/\/www.census.gov\/newsroom\/blogs\/random-samplings\/2023\/05\/racial-ethnic-diversity-adults-children.html (2024). Accessed 24 Nov 2024."},{"issue":"2","key":"19214_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.23157","volume":"112","author":"JG Ford","year":"2008","unstructured":"Ford JG, Howerton MW, Lal GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112(2):228\u201342.","journal-title":"Cancer."},{"issue":"18","key":"19214_CR19","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1002\/cncr.33600","volume":"127","author":"D Habr","year":"2021","unstructured":"Habr D, Ferdinand R. Addressing racial\/ethnic disparities in cancer clinical trials: everyone has a role to play. Cancer. 2021;127(18):3282\u20139.","journal-title":"Cancer."},{"key":"19214_CR20","unstructured":"United States Census Bureau: Census Illuminates Racial and Ethnic Composition of the Country. https:\/\/www.census.gov\/library\/stories\/2021\/08\/improved-race-ethnicity-measures-reveal-united-states-population-much-more-multiracial.html (2020). Accessed 9 Jan 2024."},{"key":"19214_CR21","unstructured":"Antidote Technologies: Inc. 5 ways to increase diversity in your clinical trial. https:\/\/www.antidote.me\/blog\/increasing-diversity-in-your-clinical-trial (2024). Accessed 9 Jan 2024."},{"key":"19214_CR22","unstructured":"PhRMA: Improving clinical trial diversity is critical to health equity. https:\/\/phrma.org\/Equity\/clinical-trial-diversity (2024). Accessed 9 Jan 2024."},{"issue":"21","key":"19214_CR23","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1001\/jama.2024.16009","volume":"332","author":"RK Metcalfe","year":"2024","unstructured":"Metcalfe RK, Park JJH. Diversity action plans in clinical trials. JAMA. 2024;332(21):1785\u20136.","journal-title":"JAMA."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19214-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:27:57Z","timestamp":1778869677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19214-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["19214"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19214-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author(s) declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Diclosure"}}]}}